Coloplast cuts annual organic revenue growth outlook through 2030 to 5-7% from 7-8%
Coloplast cut its annual organic revenue growth ambition through FY 2029/30 to 5-7% from 7-8%, and now targets a mid-20% constant-currency EBIT margin and ROIC around 20%. For FY 2026/27, it forecasts 5-7% organic growth and a constant-currency EBIT margin around 25%.
1. Revised outlook
Coloplast cut its annual organic revenue growth ambition through FY 2029/30 to 5-7% from 7-8%. It now targets a constant-currency EBIT margin in the mid-20% range and ROIC around 20%, compared with a previous target above 20%.
2. Near-term targets and costs
For FY 2026/27, Coloplast forecasts organic revenue growth of 5-7% and a constant-currency EBIT margin before special items around 25%. The downgrade reflects US biologics reimbursement changes, healthcare pricing pressure, inflation and increased investment in innovation and selected commercial areas. A cost-saving program aims to free up around DKK 500 million, with full impact in FY 2027/28.
